Moreover, expansion and activation of CD103+ cDC1 progenitors at the tumor site by simultaneously administering FLT3L and poly I:C enhances tumor responses to BRAF inhibitors and PD-L1 blockade (26). Here, CD274 is linked to neoplasm.